OSUR - OraSure Technologies Inc Stock Price, Fair Value and News

5.24USD-0.01 (-0.19%)Market Closed

Market Summary

USD5.24-0.01

Market Closed

-0.19%

OSUR Stock Price

View Fullscreen

OSUR RSI Chart

OSUR Valuation

Market Cap

387.4M

Price/Earnings (Trailing)

7.22

Price/Sales (Trailing)

0.96

EV/EBITDA

1.26

Price/Free Cashflow

2.85

OSUR Price/Sales (Trailing)

OSUR Profitability

EBT Margin

13.87%

Return on Equity

12.46%

Return on Assets

11.11%

Free Cashflow Yield

35.05%

OSUR Fundamentals

OSUR Revenue

Revenue (TTM)

405.5M

Rev. Growth (Yr)

-38.35%

Rev. Growth (Qtr)

-14.92%

OSUR Earnings

Earnings (TTM)

53.7M

Earnings Growth (Yr)

27.04%

Earnings Growth (Qtr)

79.88%

Breaking Down OSUR Revenue

Last 7 days

-9.3%

Last 30 days

-22.8%

Last 90 days

-34.9%

Trailing 12 Months

-21.3%

How does OSUR drawdown profile look like?

OSUR Financial Health

Current Ratio

9.77

OSUR Investor Care

Shares Dilution (1Y)

0.75%

Diluted EPS (TTM)

0.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	474.7M	479.9M	452.7M	405.5M
2022	242.8M	265.4M	328.0M	387.5M
2021	199.4M	227.1M	233.0M	233.7M
2020	156.1M	146.5M	154.9M	171.7M
2019	169.9M	165.1M	155.2M	154.6M
2018	176.5M	180.0M	183.5M	181.7M
2017	131.7M	140.5M	150.5M	167.1M
2016	121.7M	122.7M	125.1M	128.2M
2015	110.0M	114.0M	116.0M	119.7M
2014	101.3M	103.4M	106.6M	106.5M
2013	88.0M	89.8M	92.3M	98.9M
2012	85.4M	89.0M	89.4M	87.8M
2011	74.5M	74.3M	77.0M	81.9M
2010	0	76.4M	75.7M	75.0M
2009	0	0	0	77.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of OraSure Technologies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 26, 2024	datin james a	acquired	20,001	6.2175	3,217	-
Mar 26, 2024	datin james a	sold (taxes)	-5,415	6.2175	-871	-
Mar 01, 2024	mcgrath kenneth j	acquired	-	-	58,759	chief financial officer
Mar 01, 2024	weber kathleen gallagher	sold (taxes)	-31,668	7.1925	-4,403	chief product officer
Mar 01, 2024	eglinton manner carrie	sold (taxes)	-213,236	7.1925	-29,647	president & ceo
Mar 01, 2024	mcgrath kenneth j	sold (taxes)	-40,393	7.1925	-5,616	chief financial officer
Mar 01, 2024	anthony michele marie	sold (taxes)	-19,477	7.1925	-2,708	svp finance & cao
Mar 01, 2024	eglinton manner carrie	acquired	-	-	260,688	president & ceo
Mar 01, 2024	anthony michele marie	acquired	-	-	24,336	svp finance & cao
Mar 01, 2024	weber kathleen gallagher	acquired	-	-	41,171	chief product officer

Which funds bought or sold OSUR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	FLAGSHIP HARBOR ADVISORS, LLC	sold off	-100	-112,037	-	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	new	-	1,274,050	1,274,050	0.03%
Apr 15, 2024	One Wealth Advisors, LLC	reduced	-0.27	-62,124	184,352	0.03%
Apr 15, 2024	Counterpoint Mutual Funds LLC	new	-	131,450	131,450	0.03%
Apr 12, 2024	Murphy Pohlad Asset Management LLC	unchanged	-	-173,943	521,827	0.20%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	-2,002	6,009	-%
Apr 10, 2024	Wedmont Private Capital	reduced	-0.68	-20,812	64,169	-%
Apr 05, 2024	CWM, LLC	reduced	-12.52	-12,000	22,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	7.2	-389	3,296	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	2.56	-629,417	2,097,920	0.01%

Are Funds Buying or Selling OSUR?

Are funds buying OSUR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OSUR

No. of Funds

Unveiling OraSure Technologies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	7.23%	5,309,456	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	5.3%	3,906,687	SC 13G
Jan 22, 2024	blackrock inc.	17.2%	12,622,864	SC 13G/A
Feb 09, 2023	vanguard group inc	7.06%	5,129,077	SC 13G/A
Feb 07, 2023	managed account advisors llc	0.1%	34,069	SC 13G/A
Feb 02, 2023	camber capital management lp	5.85%	2,013	SC 13G
Jan 23, 2023	blackrock inc.	18.9%	13,718,269	SC 13G/A
Feb 08, 2022	earnest partners llc	6.8%	4,871,379	SC 13G
Jan 28, 2022	blackrock inc.	19.3%	13,893,887	SC 13G/A
Jan 26, 2022	managed account advisors llc	6.0%	4,321,379	SC 13G/A

Recent SEC filings of OraSure Technologies Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	8-K	Current Report
Apr 04, 2024	ARS	ARS
Apr 04, 2024	DEFA14A	DEFA14A
Apr 03, 2024	DEF 14A	DEF 14A
Mar 28, 2024	4	Insider Trading
Mar 22, 2024	PRE 14A	PRE 14A
Mar 11, 2024	10-K	Annual Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to OraSure Technologies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.7B	40.1B	-5.83%	1.66%	32.1	4.58	-8.12%	-17.45%
BDX	67.1B	19.5B	-2.32%	-8.43%	53.41	3.44	4.02%	-22.04%
ALGN	22.6B	3.9B	-4.99%	-13.70%	50.69	5.84	3.42%	23.09%
BAX	20.1B	14.8B	-4.86%	-7.71%	7.56	1.35	2.12%	209.17%
MID-CAP
ATR	9.1B	3.5B	-0.64%	16.68%	32.12	2.62	4.97%	18.89%
HSIC	9.0B	12.3B	-5.34%	-15.09%	21.69	0.73	-2.44%	-22.68%
BIO	8.5B	2.7B	-12.68%	-39.24%	-13.34	3.18	-4.68%	82.43%
XRAY	6.3B	4.0B	-7.94%	-25.15%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-1.55%	17.10%	-564.74	9.35	33.86%	89.83%
PDCO	2.3B	6.6B	-3.92%	-2.28%	11.91	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-5.32%	-19.06%	-1.85	0.39	7.73%	-1066.14%
ANIK	381.5M	166.7M	1.82%	-7.51%	-4.61	2.29	6.67%	-456.34%
ANGO	253.5M	324.0M	17.44%	-27.90%	-1.32	0.78	-3.19%	-337.41%
APYX	45.7M	52.3M	-25.42%	-56.00%	-2.44	0.87	17.61%	19.28%
AEMD	3.7M	3.7M	-14.97%	255.00%	-0.3	0.99	5.77%	8.23%

OraSure Technologies Inc News

Latest updates

OraSure Technologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-14.9%	76.00	89.00	85.00	155	123	116	80.00	68.00	64.00	54.00	58.00	59.00	63.00	48.00	39.00	29.00	32.00	50.00	36.00	39.00	30.00
Gross Profit	-20.8%	35.00	44.00	26.00	66.00	50.00	47.00	28.00	24.00	27.00	21.00	31.00	38.00	38.00	30.00	-	17.00	16.00	30.00	22.00	25.00	18.00
Operating Expenses	-6.6%	31.00	33.00	33.00	41.00	35.00	46.00	49.00	40.00	37.00	34.00	29.00	28.00	30.00	26.00	-	27.00	24.00	26.00	9.00	20.00	22.00
S&GA Expenses	-20.9%	7.00	9.00	9.00	12.00	11.00	13.00	12.00	13.00	11.00	14.00	10.00	10.00	9.00	8.00	-	10.00	7.00	8.00	9.00	8.00	7.00
R&D Expenses	-17.9%	7.00	9.00	8.00	11.00	8.00	10.00	9.00	9.00	9.00	9.00	8.00	9.00	10.00	8.00	-	7.00	6.00	6.00	5.00	5.00	4.00
EBITDA Margin	20.3%	0.19*	0.16*	0.13*	0.09*	0.00*	-0.08*	-0.16*	-0.09*	0.01*	0.08*	0.15*	0.12*	-	-	-	-	-	-	-	-	-
Income Taxes	-72.4%	1.00	2.00	-0.17	-0.22	-0.17	-1.14	-1.17	4.00	1.00	2.00	4.00	7.00	6.00	4.00	-	1.00	1.00	2.00	1.00	1.00	-0.03
Earnings Before Taxes	53.4%	21.00	14.00	-4.96	27.00	16.00	4.00	-19.76	-16.00	-8.93	-12.91	2.00	10.00	8.00	5.00	-	-9.18	-6.62	5.00	14.00	6.00	-3.29
EBT Margin	24.7%	0.14*	0.11*	0.09*	0.06*	-0.04*	-0.12*	-0.22*	-0.15*	-0.04*	0.03*	0.11*	0.07*	-	-	-	-	-	-	-	-	-
Net Income	79.9%	20.00	11.00	-4.80	27.00	16.00	6.00	-18.59	-19.94	-10.39	-15.01	-1.36	4.00	2.00	1.00	-	-10.49	-7.33	2.00	13.00	4.00	-3.26
Net Income Margin	23.3%	0.13*	0.11*	0.09*	0.06*	-0.05*	-0.13*	-0.24*	-0.19*	-0.10*	-0.05*	0.02*	-0.02*	-	-	-	-	-	-	-	-	-
Free Cashflow	13.5%	40.00	35.00	56.00	5.00	3.00	14.00	-14.89	-56.04	-7.17	-23.70	-10.95	-15.45	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	5.3%	483	458	454	459	444	432	429	436	461	456	465	456	454	436	421	325	349	339	327	319	316
Current Assets	8.4%	386	356	342	344	325	280	267	268	299	289	285	292	289	303	318	223	225	223	209	205	219
Cash Equivalents	33.5%	290	218	186	90.00	84.00	75.00	66.00	71.00	117	135	158	178	161	163	174	83.00	76.00	85.00	73.00	70.00	88.00
Inventory	-19.7%	48.00	59.00	73.00	77.00	96.00	79.00	71.00	62.00	53.00	54.00	48.00	40.00	32.00	30.00	28.00	23.00	23.00	25.00	26.00	26.00	23.00
Net PPE	-5.4%	45.00	48.00	49.00	57.00	59.00	85.00	94.00	98.00	73.00	78.00	72.00	65.00	52.00	39.00	34.00	32.00	30.00	29.00	28.00	26.00	24.00
Goodwill	1.9%	36.00	35.00	36.00	35.00	35.00	34.00	36.00	40.00	40.00	40.00	41.00	40.00	40.00	39.00	35.00	35.00	36.00	29.00	29.00	29.00	10.00
Liabilities	-2.6%	52.00	54.00	59.00	65.00	80.00	90.00	85.00	71.00	80.00	68.00	60.00	53.00	56.00	49.00	39.00	35.00	42.00	38.00	39.00	38.00	32.00
Current Liabilities	-3.4%	40.00	41.00	46.00	55.00	69.00	72.00	65.00	56.00	68.00	54.00	47.00	45.00	46.00	37.00	31.00	26.00	33.00	29.00	30.00	27.00	28.00
Shareholder's Equity	6.4%	431	405	394	394	364	342	344	365	381	388	405	404	399	388	382	290	307	301	288	281	283
Retained Earnings	19.3%	-83.93	-104	-115	-110	-137	-153	-159	-140	-120	-110	-95.04	-93.68	-97.45	-99.31	-100	-89.86	-82.53	-84.97	-98.05	-102	-99.19
Additional Paid-In Capital	0.6%	530	526	524	522	520	518	516	514	511	509	506	505	505	503	499	402	402	401	400	399	401
Accumulated Depreciation	1.2%	85.00	84.00	84.00	72.00	70.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.1%	74.00	73.00	73.00	73.00	73.00	72.00	72.00	72.00	72.00	72.00	72.00	72.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	368	-	-	-	198	-	-	-	728	-	-	-	829	-	-	-	570	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	12.0%	41,366	36,947	57,268	6,002	-18,012	16,299	-9,668	-35,821	-12,784	-19,126	921	-4,393	3,611	4,380	-4,683	2,499	-1,034	6,177	4,133	528	14,283
Share Based Compensation	20.7%	3,127	2,590	2,357	2,655	2,522	2,296	3,280	3,524	2,652	2,218	1,473	1,464	1,226	1,865	2,672	1,376	774	1,435	617	1,231	2,711
Cashflow From Investing	1288.4%	30,554	-2,571	37,155	1,016	25,573	-2,224	7,675	-9,939	-6,277	-9,594	-12,295	22,665	-10,113	-17,062	-1,001	14,147	-9,897	8,523	-2,209	-16,214	65.00
Cashflow From Financing	49.6%	-355	-705	-632	-1,331	-801	-488	-1,144	-1,395	235	-522	-346	-2,184	929	1,376	94,731	-4,557	-163	-136	-51.00	-4,332	-394
Buy Backs	-81.0%	38.00	200	460	1,203	246	54.00	905	1,049	189	47.00	147	1,730	12.00	12.00	656	1,408	1.00	7.00	109	3,595	411

OSUR Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
NET REVENUES:
Total revenue	$ 405,472	$ 387,479	$ 233,674
COST OF PRODUCTS AND SERVICES SOLD	233,820	239,041	116,074
Gross profit	171,652	148,438	117,600
OPERATING EXPENSES:
Research and development	33,728	36,237	34,170
Sales and marketing	36,319	49,238	44,751
General and administrative	58,191	68,206	50,328
Loss on impairments	10,829	17,101	0
Change in the estimated fair value of acquisition-related contingent consideration	(99)	(188)	(1,485)
Total operating expenses	138,968	170,594	127,764
Operating income (loss)	32,684	(22,156)	(10,164)
OTHER INCOME	23,574	6,481	872
Income (loss) before income taxes	56,258	(15,675)	(9,292)
INCOME TAX EXPENSE	2,603	1,458	13,706
NET INCOME (LOSS)	$ 53,655	$ (17,133)	$ (22,998)
INCOME (LOSS) PER SHARE:
Basic earnings per share (in US dollars per share)	$ 0.73	$ (0.24)	$ (0.32)
Diluted earnings per share (in US dollars per share)	$ 0.72	$ (0.24)	$ (0.32)
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
Basic weighted average number of shares outstanding (in shares)	73,348	72,505	71,981
Diluted weighted average number of shares outstanding (in shares)	74,389	72,505	71,981
Products and services
NET REVENUES:
Total revenue	$ 402,222	$ 378,047	$ 226,897
Other
NET REVENUES:
Total revenue	$ 3,250	$ 9,432	$ 6,777

OSUR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 290,407,000	$ 83,980,000
Short-term investments	0	26,867,000
Accounts receivable, net of allowance for doubtful accounts of $1,216 and $2,365	40,171,000	70,797,000
Inventories	47,614,000	95,704,000
Prepaid expenses	6,041,000	6,273,000
Other current assets	2,226,000	41,569,000
Total current assets	386,459,000	325,190,000
Noncurrent Assets:
Property, plant and equipment, net	45,420,000	59,413,000
Operating right-of-use assets, net	12,270,000	10,399,000
Finance right-of-use assets, net	576,000	1,293,000
Intangible assets, net	1,206,000	11,694,000
Goodwill	35,696,000	35,104,000
Other noncurrent assets	1,218,000	1,087,000
Total noncurrent assets	96,386,000	118,990,000
TOTAL ASSETS	482,845,000	444,180,000
Current Liabilities:
Accounts payable	13,151,000	38,020,000
Deferred revenue	1,559,000	2,273,000
Accrued expenses and other current liabilities	22,710,000	25,762,000
Finance lease liability	539,000	1,179,000
Operating lease liability	1,577,000	1,764,000
Acquisition-related contingent consideration obligation	0	65,000
Total current liabilities	39,536,000	69,063,000
Noncurrent Liabilities:
Finance lease liability	226,000	503,000
Operating lease liability	11,162,000	9,101,000
Acquisition-related contingent consideration obligation	0	99,000
Other noncurrent liabilities	696,000	581,000
Deferred income taxes	554,000	408,000
Total noncurrent liabilities	12,638,000	10,692,000
TOTAL LIABILITIES	52,174,000	79,755,000
Commitments and contingencies (Note 14)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued	0	0
Common stock, par value $.000001, 120,000 shares authorized, 73,528 and 72,734 shares issued and outstanding	0	0
Additional paid-in capital	529,543,000	520,446,000
Accumulated other comprehensive loss	(14,941,000)	(18,435,000)
Accumulated deficit	(83,931,000)	(137,586,000)
Total stockholders' equity	430,671,000	364,425,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 482,845,000	$ 444,180,000

About OraSure Technologies Inc

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's diagnostic products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene Ã‚â€¢ GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene Ã‚â€¢ GUT DNA and RNA collection devices; and OMNIgeneÃ‚â€¢GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

CEO	Ms. Carrie Eglinton Manner
WEBSITE	orasure.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	840

OraSure Technologies Inc Frequently Asked Questions

What is the ticker symbol for OraSure Technologies Inc? What does OSUR stand for in stocks?

OSUR is the stock ticker symbol of OraSure Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of OraSure Technologies Inc (OSUR)?

As of Wed Apr 17 2024, market cap of OraSure Technologies Inc is 387.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OSUR stock?

You can check OSUR's fair value in chart for subscribers.

What is the fair value of OSUR stock?

You can check OSUR's fair value in chart for subscribers. The fair value of OraSure Technologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of OraSure Technologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OSUR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is OraSure Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether OSUR is over valued or under valued. Whether OraSure Technologies Inc is cheap or expensive depends on the assumptions which impact OraSure Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OSUR.

What is OraSure Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, OSUR's PE ratio (Price to Earnings) is 7.22 and Price to Sales (PS) ratio is 0.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OSUR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on OraSure Technologies Inc's stock?

In the past 10 years, OraSure Technologies Inc has provided -0.027 (multiply by 100 for percentage) rate of return.